Drug search by name

Robitussin Multi-Symptom Cold and Zelboraf

Determining the interaction of Robitussin Multi-Symptom Cold and Zelboraf and the possibility of their joint administration.

Check result:

Robitussin Multi-Symptom Cold <> Zelboraf

Relevance: 04.12.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Vemurafenib may increase the blood levels and effects of dextromethorphan. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Contact your doctor if your condition changes or you experience increased side effects. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

MONITOR: Coadministration with vemurafenib may increase the plasma concentrations of drugs that are substrates of the CYP450 1A2 and/or 2D6 isoenzymes. The mechanism is decreased clearance due to inhibition of CYP450 1A2 and 2D6 activity by vemurafenib. The interaction has been studied with caffeine and dextromethorphan, probe substrates for CYP450 1A2 and 2D6, respectively. In an in vivo phenotypic cocktail drug-drug interaction study in patients with cancer, caffeine systemic exposure (AUC) increased by 2.6-fold when a single dose of the CYP probe substrate cocktail was administered following treatment with vemurafenib 960 mg twice daily for 15 days, while dextromethorphan AUC increased by 47%.

MANAGEMENT: Caution is advised if vemurafenib must be used concurrently with drugs that undergo metabolism by CYP450 1A2 and/or 2D6. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever vemurafenib is added to or withdrawn from therapy. Concomitant use of vemurafenib and substrates of CYP450 1A2 and/or 2D6 with a narrow therapeutic index (e.g., antiarrhythmics; theophylline) should be avoided if possible.

References

"Product Information. Zelboraf (vemurafenib)." Genentech, South San Francisco, CA.

Robitussin Multi-Symptom Cold

Generic Name: dextromethorphan / guaifenesin / phenylephrine

Brand name: Broncotron-D, Duravent DM, Giltuss, Mucinex Fast-Max Severe Congestion & Cough, Phlemex Forte, Robitussin Children's Cough & Cold CF, Robitussin Multi-Symptom Cold, Tusicof, Tussin CF, Vanacof DM, Z-tuss DM, Deconex DMX, Maxiphen DM, Tussex, Tussafed-EX, Sinutuss DM, GDP-EX, Duraphen DM, TriTuss, TriTuss-ER, Tussafed-EX Drops, Certuss-D, Dacex-PE, Anextuss, Dexcon-PE, Zotex LAX, Dacex-DM, Dexcon-DM, Duraphen II DM, Duraphen Forte, G-Phen DM, Despec DM Syrup, Phlemex-PE, Guaphen Forte, Guaphen II DM, Z-Dex, Aquatab C, Robafen CF, DuraMAX, Tusso-XR, Tusso-DM, Robitussin Cough & Cold CF, Ambi 40/1000/60, Maxiphen-G DM, Robitussin Pediatric Cough & Cold CF, Deconex DM, PDM GG, ExeTuss-DM, Endacon DM, Giltuss TR, Q-Tussin CF, Tusso-DMR, Execof ER, Dynatuss EX, Zotex, Robitussin Cough & Cold CF To Go, Zotex-EX, Endacon, Robitussin Cough & Cold CF Max, Mucinex Children's Multi-Symptom Cold, Supress-DX, Tussi-Pres, Tussi-Pres Pediatric, Pres Gen Pediatric, Pres Gen, Robitussin Peak Cold Max Strenth Multi-S, G-Tusicof, Adult Severe Congestion & Cough, Giltuss Pediatrics, Desgen DM, G-Supress DX, Tusslin, Desgen Pediatric, G-Tron Ped, Broncotron Ped, Tusslin Pediatric, Nivanex DMX, Relhist DMX, Giltuss Cough & Cold, Children Giltuss Cough & Cold, VanaTab DM, Tukol Cough & Cold, Robitussin Peak Cold Multi-Sympton Cold, Deconex DMX Poly, Tussidex

Synonyms: n.a.

What is Robitussin Multi-Symptom Cold?

Zelboraf

Generic Name: vemurafenib

Brand name: Zelboraf

Synonyms: n.a.

What is Zelboraf?

+ Add a drug Remove all

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

The list of popular interactions